Continuous Manufacturing Has a Strong Impact on Drug Quality

In 2012*, FDA expounded on the benefits of continuous manufacturing, which are greater reliability, safety, efficiency, responsiveness/flexibility, and reducing costs.

Since 2012, Takasago has been working on utilizing our specialized homogeneous catalyst technology in continuous flow manufacturing.

Although we faced a lot of difficulties to achieve that, now the continuous flow manufacturing is one of our specialties.

Takasago has Pipe Flow Reactor (PFR) and Continuous Stirred Tank Reactor (CSTR) and Intermittent Stirred Tank Reactor (iSTR) in R&D and Iwata and Kakegawa factory. They can be used for the production process for pharmaceutical intermediates.

From 2015, we carried out the commercial production by the continuous flow manufacturing facility. Now, the total production has reached 100 MT (million metric tonnes) at IWATA.In 2016, FDA inspected our Iwata facility.

In 2018, Takasago succeeded in production of ton scale with Lithium aluminum hydride (LAH) reducing agent by using our continuous flow manufacturing technology.

Takasago keeps developing continuous flow manufacturing equipment as a differentiated technology and contribute to customers’ satisfaction.

* “FDA Perspective on Continuous Manufacturing”, S. Chatterjee, IFPAC Annu. Meet. Jan. 22-25, 2012, Baltimore. MD, USA. PDF

• Org. Process Res. Dev. 2016, 20, 1305–1320. doi.10.1021/acs.oprd.6b00137
• Org. Process Res. Dev. 2017, 21, 1447−1451. doi.10.1021/acs.oprd.7b00234
• Org. Process Res. Dev. 2019, 23, 452–461. doi.10.1021/acs.oprd.8b00338

Progress of continuous flow manufacturing

Facilities for Continuous Methodology

Flow Applications at Takasago